Campbell Alliance to Present Workshop on Common Errors in Valuation Models at BIO Advanced Business Development Course in Europe

October 31, 2006

Campbell Alliance, the leading management consulting firm specializing in the pharmaceutical and biotech industries, today announced that Ben Bonifant, Vice President of its Business Development Practice, will be presenting a workshop as part of the BIO (Biotechnology Industry Organization) Advanced Business Development Course being held from November 3−5, 2006 at Hilton Hotel in Dusseldorf, Germany.  The course immediately precedes BIO-Europe, a partnering event for top-level pharmaceutical and biotechnology business development executives and CEOs.

Mr. Bonifant's workshop, "11 Missteps in Valuation and How to Avoid Them," will discuss some of the more frequently encountered errors in valuation models. The audience will then participate in an interactive discussion of how decision makers can increase the likelihood that the models they rely on reflect the "real world" of pharmaceutical commercialization. The workshop will be conducted on Friday, November 3, from 5:00 p.m. to 6:00 p.m.  Mr. Bonifant presented a similar workshop at the Advanced Business Development Course held in conjunction with BIO-Windhover in the US in May.

The list of potential missteps related to valuations is long.  Mr. Bonifant's "top 11," which he will cover during this workshop session, are: 

    1.  Prevalent means relevant.

    2.  Any available data are good.

    3.  It's all about us.

    4.  It's all about efficacy.

    5.  All patients are compliant.

    6.  The product will sell itself.

    7.  A ready market awaits us.

    8.  All patients will have access.

    9.  Assumptions about average wholesale price are valid.

  10.  The price will never increase.

  11.  Post-marketing trials are free.

The BIO Advanced Business Development Course is designed for business development professionals interested in bringing their skills in valuation, due diligence, negotiations, and contracts to the next level. Since 2004, BIO has offered the course—in collaboration with the Licensing Executives Society—exclusively for life science business development professionals. 

For more information, please visit or

About the Business Development Practice at Campbell Alliance

The Business Development Practice at Campbell Alliance helps licensing executives achieve an edge over the competition.  Our consultants provide experienced counsel to clients who need assistance developing business development strategies, identifying partners, prioritizing targets, evaluating opportunities, and negotiating deals.

The firm's team includes seasoned consultants and industry professionals in pharmaceutical and biotech business development who have identified, assessed, and executed numerous in-licensing deals.  They have also been valuable in aiding out-licensors, helping clients improve internal processes for pharmaceutical business development, and assisting top executives chart new strategies in corporate development.

About Campbell Alliance

Campbell Alliance is the leading management consulting firm specializing in the pharmaceutical and biotechnology industries.  The firm's clients include most of the world's "top 20" pharmaceutical companies, as well as numerous emerging and midsize firms.  Campbell Alliance is organized into practice areas, each specializing in a critical industry function, including Brand Management, Business Development, Clinical Development, Managed Markets, and Sales.  From its locations in Raleigh, N.C., Parsippany, N.J., Los Angeles, San Francisco, Chicago, Boston, and New York City, the firm serves clients throughout North America, Europe, and Japan.  For more information on Campbell Alliance, please visit

inVentiv Health Consulting offers world class healthcare consulting services.

Media Contact:

Stephanie Koenig